Edward Tenthoff
Stock Analyst at Piper Sandler
(2.22)
# 2,680
Out of 4,876 analysts
176
Total ratings
39.08%
Success rate
-3.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STRO Sutro Biopharma | Upgrades: Overweight | $2 | $0.80 | +151.22% | 7 | Jun 16, 2025 | |
| BMEA Biomea Fusion | Assumes: Overweight | $7 | $1.90 | +268.42% | 1 | Jun 3, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $6 → $9 | $7.24 | +24.31% | 4 | May 29, 2025 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $16 → $12 | $10.02 | +19.82% | 1 | May 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $7.85 | +78.34% | 7 | May 2, 2025 | |
| IPSC Century Therapeutics | Maintains: Overweight | $4 → $2 | $0.56 | +256.51% | 8 | Mar 20, 2025 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $53 → $48 | $9.94 | +382.90% | 6 | Feb 28, 2025 | |
| MESO Mesoblast | Reiterates: Overweight | $15 → $24 | $11.06 | +117.00% | 5 | Feb 7, 2025 | |
| LEGN Legend Biotech | Reiterates: Overweight | $78 | $35.80 | +117.88% | 4 | Dec 30, 2024 | |
| XNCR Xencor | Upgrades: Overweight | $20 → $30 | $8.28 | +262.32% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $45 | $16.02 | +180.90% | 11 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $296 | $321.20 | -7.85% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $69 | $27.40 | +151.82% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $7.02 | +825.93% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.68 | +971.43% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $11.40 | +207.02% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $4.75 | +321.05% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.33 | +125.56% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.79 | +280.61% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.64 | +244.83% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $47.37 | +121.66% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.07 | +460.75% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.96 | +155.10% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $44.54 | +25.73% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $9.06 | +2,637.31% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $2.00 | +4,400.00% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $6 | $0.48 | +1,150.00% | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $9.41 | +1,812.86% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $17.50 | +151.43% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $7.34 | +404.43% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $3.15 | +20,672,915.87% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $561.04 | -36.90% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.23 | +10,875.61% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $445.70 | -27.53% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $43.99 | -18.16% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.50 | +1,572.24% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.93 | +16,029.90% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $53 | $1.23 | +4,208.94% | 2 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.61 | +227,127.45% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $523.60 | - | 11 | Feb 13, 2017 |
Sutro Biopharma
Jun 16, 2025
Upgrades: Overweight
Price Target: $2
Current: $0.80
Upside: +151.22%
Biomea Fusion
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.90
Upside: +268.42%
Fulcrum Therapeutics
May 29, 2025
Maintains: Overweight
Price Target: $6 → $9
Current: $7.24
Upside: +24.31%
iTeos Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $10.02
Upside: +19.82%
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $7.85
Upside: +78.34%
Century Therapeutics
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.56
Upside: +256.51%
Dyne Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $9.94
Upside: +382.90%
Mesoblast
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $11.06
Upside: +117.00%
Legend Biotech
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $35.80
Upside: +117.88%
Xencor
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $8.28
Upside: +262.32%
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $16.02
Upside: +180.90%
Nov 18, 2024
Reiterates: Overweight
Price Target: $296
Current: $321.20
Upside: -7.85%
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $27.40
Upside: +151.82%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $7.02
Upside: +825.93%
Nov 5, 2024
Initiates: Overweight
Price Target: $18
Current: $1.68
Upside: +971.43%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $11.40
Upside: +207.02%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $4.75
Upside: +321.05%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.33
Upside: +125.56%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.79
Upside: +280.61%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.64
Upside: +244.83%
Jun 17, 2024
Reiterates: Overweight
Price Target: $105
Current: $47.37
Upside: +121.66%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.07
Upside: +460.75%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.96
Upside: +155.10%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $44.54
Upside: +25.73%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $9.06
Upside: +2,637.31%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $2.00
Upside: +4,400.00%
Nov 4, 2022
Maintains: Overweight
Price Target: $13 → $6
Current: $0.48
Upside: +1,150.00%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $9.41
Upside: +1,812.86%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $17.50
Upside: +151.43%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $7.34
Upside: +404.43%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $3.15
Upside: +20,672,915.87%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $561.04
Upside: -36.90%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.23
Upside: +10,875.61%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $445.70
Upside: -27.53%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $43.99
Upside: -18.16%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.50
Upside: +1,572.24%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.93
Upside: +16,029.90%
Jan 6, 2020
Maintains: Overweight
Price Target: $26 → $53
Current: $1.23
Upside: +4,208.94%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.61
Upside: +227,127.45%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $523.60
Upside: -